SCHEMBL2982151

SCHEMBL2982151

Nc1cnc2[nH]c(-c3ccnc(Cl)c3)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.42
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
MAPT P10636 5/20 0.37
NPC1 O15118 5/20 0.37
GAA P10253 4/20 0.37
TP53 P04637 4/20 0.37
RAB9A P51151 4/20 0.37
KDM4E B2RXH2 4/20 0.37
POLB P06746 4/20 0.37
USP2 O75604 3/20 0.37
THRB P10828 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
CACNA1B Q00975 2/20 0.37
APBA1 Q02410 2/20 0.37
LMNA P02545 1/20 0.37
ADORA2A P29274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984904 0.83 MAP4K4 (0.39) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL983953 0.82 ALDH1A1 (0.45) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL986012 0.82 MEN1 (0.47) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL988039 0.81 ALDH1A1 (0.56) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL984463 0.81 HRH1 (0.48) IDO1MEN1KMT2AALDH1A1HPGD
SCHEMBL5621043 0.79 ALDH1A1 (0.54) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL2977867 0.78 NPC1 (0.43) IDO1MEN1KMT2AALDH1A1HPGD
SCHEMBL986878 0.78 ALDH1A1 (0.54) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL2973981 0.76 KDM4E (0.39) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL987203 0.76 MAPT (0.60) MEN1KMT2AALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786113-B2 Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents HOFFMAN-LA ROCHE INC. (US) 2010-08-31 US disclosed
US-20080009492-A1 Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2008-01-10 US disclosed
EP-1831218-A2 CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-09-12 EP disclosed
WO-2006066914-A2 CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009492-A1 Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents RCC2, ACMSD, CPS1 IDO1 2641/4885MEN1 148/4885KMT2A 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.